<DOC>
	<DOCNO>NCT02630186</DOCNO>
	<brief_summary>This clinical research study carry two part , Phase 1 Phase 2 . The primary purpose Phase 1 portion study observe safety combination rociletinib MPDL3280A EGFR-mutant NSCLC patient . The primary purpose Phase 2 portion study evaluate safety anti-tumor effect combination rociletinib MPDL3280A , best dos combination determine Phase 1 , patient EGFR-mutant NSCLC .</brief_summary>
	<brief_title>A Phase 1b/2 Study Safety Efficacy Rociletinib Combination With MPDL3280A Patients With Advanced Metastatic EGFR-mutant NSCLC</brief_title>
	<detailed_description>This Phase 1b/2 , open-label , non-randomized , multicenter study evaluate safety efficacy rociletinib administer combination MPDL3280A . Phase 1 : This dose find phase study . Patients enrol available Dosing Cohort . Patients progress prior first- second-generation EGFR TKI , regardless T790M mutation status , enrol . Phase 2 : Patients enrol 2 group . Group A enroll eligible first-line patient EGFR TKI treatment-na誰ve chemotherapy-na誰ve . Group B enroll eligible patient progress prior first- second-generation EGFR TKI , regardless T790M mutation status .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>ECOG performance status 0 1 Adequate hematological biological function , confirm defined laboratory value Histologically cytologically document metastatic unresectable , locally advanced metastatic NSCLC , one activate EGFR mutation ( eg , G719X , exon 19 deletion , L858R , L861Q ) absence exon 20 insertion Measurable disease define RECIST v1.1 Biopsy tumor tissue central evaluation , within 60 day prior first day study treatment For Phase 1 Phase 2 Group B , progression prior 1st 2nd generation EGFR TKI ( eg , erlotinib , gefitinib , afatinib ) . Previous chemotherapy NSCLC allow . For Phase 2 Group A , EGFR TKI treatmentna誰ve chemotherapyna誰ve Unresolved toxicities prior therapy Symptomatic , untreated unstable central nervous system leptomeningeal metastases Previous treatment rociletinib MPDL3280A , 3rd generation EGFR TKI ( eg , AZD9291 , HM61713 ) , PD 1 axis target therapy ( eg , anti PD 1 antiPD L1 ) Prior treatment CD137 agonists immune checkpoint blockade therapy , include antiCTLA4 therapeutic antibody Uncontrolled pleural effusion , pericardial effusion ascites require recurrent drainage procedure Uncontrolled hypercalcemia symptomatic hypercalcemia require continue use bisphosphonate therapy denosumab ( bisphosphonate use prevention skeletal event allow ) Known hypersensitivity component MPDL3280A rociletinib formulation history hypersensitivity chimeric humanize antibody fusion protein History autoimmune disease History prior allogeneic hematopoietic stem cell transplantation prior solid organ transplantation Treatment systemic immunosuppressive medication within 2 week prior first day study treatment ( inhaled corticosteroid mineralocorticoid allow ) Live attenuate vaccine within 4 week prior first day study treatment Active tuberculosis , active hepatitis , positive HIV status Class II IV heart failure define New York Heart Association functional classification system Untreated uncontrolled cardiovascular disease symptomatic cardiac dysfunction QTCF &gt; 450 m , inability measure QT interval ECG , personal family history long QT syndrome , requirement medication potential prolong QT interval History idiopathic pulmonary fibrosis , organize pneumonia , druginduced pneumonitis , idiopathic pneumonitis , evidence active pneumonitis screen chest computerize tomography ( CT ) scan ( history radiation pneumonitis radiation field may allow ) Other malignancy within 5 year prior enrollment , exception carcinoma situ cervix , basal squamous cell skin cancer , localize prostate cancer , ductal carcinoma situ</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>